The partnership with Trusted Health Advisors, led by industry veterans, is likely to provide Mainz Biomed with strategic advantages in navigating the U.S. market for its colorectal cancer diagnostic test. Given the involvement of Dr. Jay Wohlgemuth and Dr. Ray Tabibiazar, the collaboration could lend credibility and potentially facilitate smoother regulatory processes and market entry. The anticipation of the ReconAAsense clinical trial's commencement in 2024 further underscores the company's progress towards bringing its product to market.